Ryvu Therapeutics S.A. (9Y4)
XSTU 
Summary
9Y4 Chart
Ryvu Therapeutics S.A. (9Y4) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ryvu Therapeutics S.A. ever had a stock split?
Ryvu Therapeutics S.A. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc. CEO | XSTU Exchange | PLSELVT00013 ISIN |
| Poland Country | 328 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Ryvu Therapeutics S.A. is a pioneering clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapies aimed at treating various oncological ailments. Founded in 2007 and operating from its headquarters in Kraków, Poland, the company has positioned itself as a key player in the field of oncology, specializing in the advancement of innovative drug candidates through clinical trials. Ryvu Therapeutics is dedicated to addressing the unmet medical needs in cancer treatment by targeting complex mechanisms and pathways involved in the disease's progression. The company's research and development efforts are primarily focused on hematological malignancies and solid tumors, utilizing cutting-edge science to create therapies that can potentially transform the cancer treatment landscape.
Products and Services
Ryvu Therapeutics S.A. offers an array of promising drug candidates in various stages of clinical development, including:
- RVU120 - This lead candidate represents a significant breakthrough as a CDK8 kinase inhibitor. It showcases a strong potential for treating hematological malignancies and solid tumors. Currently in a Phase 1b clinical trial, RVU120 is being tested for its efficacy and safety in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- SEL24/MEN1703 - In collaboration with the Menarini Group, Ryvu Therapeutics has licensed this dual PIM/FLT3 kinase inhibitor, now in a Phase 2 clinical trial. This compound is designed for the treatment of acute myeloid leukemia (AML), illustrating the company's commitment to developing targeted therapies for high-impact oncological indications.
- In addition to these advanced candidates, Ryvu Therapeutics is actively working on an early pipeline featuring innovative research projects in the areas of kinases, synthetic lethality, and immuno-oncology. These early-stage candidates demonstrate the company's dedication to exploring new frontiers in cancer therapy, aiming to introduce novel concepts and treatment modalities into the oncology domain.
